2145-65-5

Upstream product

• 659-41-6 4-fluorobenzenemethanamine hydrochloride 
• 127099-85-8 N-Cyanoguanidine 
• 140-75-0 para-fluorobenzylamine 

Downstream Products

• 1333500-45-0 C₁₅H₂₀FN₅*ClH 
• 1333500-33-6 4,6-diamino-1-(4'-fluorobenzyl)-1,2-dihydro-2,2-dimethyl-1,3,5-triazine hydrochloride 

Relevant academic research and scientific papers

BIGUANIDE COMPOUND AND USE THEREOF

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Synthesis and antimicrobial activity of N1-benzyl or N 1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamines

The emergence and spread of multidrug-resistant strains of Staphylococcus aureus and Mycobacterium tuberculosis are generating a threat to public health worldwide. In the current study, a series of N1-benzyl and N 1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamine derivatives were synthesized and investigated for their antimicrobial activity against S. aureus, and Mycobacterium smegmatis which is taxonomically related to M. tuberculosis. Most of the compounds exhibited good activity against M. smegmatis as determined by comparison of diameters of the zone of inhibition of test compounds and standard antibiotics. Compound 7o showed potent antimycobacterial activity against M. smegmatis without mammalian DHFR inhibition liability. The results from this study indicate that 1-benzyl derivatives of 1,6-dihydro-1,3,5- triazine-2,4-diamines may be used as lead compounds for the discovery of antimycobacterial agents.